{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:26:24Z","timestamp":1770510384450,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,21]],"date-time":"2010-11-21T00:00:00Z","timestamp":1290297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s12013-010-9100-5","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T06:10:33Z","timestamp":1290233433000},"page":"7-12","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Amifostine in Treating Patients with Idiopathic Thrombocytopenia Purpura"],"prefix":"10.1007","volume":"59","author":[{"given":"Hui","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Chun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Qian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,21]]},"reference":[{"key":"9100_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.med.56.082103.104644","volume":"56","author":"DB Cines","year":"2005","unstructured":"Cines, D. B., & McMillan, R. (2005). Management of adult idiopathic thrombocytopenic purpura. Annual Review of Medicine, 56, 425\u2013442.","journal-title":"Annual Review of Medicine"},{"key":"9100_CR2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","volume":"103","author":"R McMillan","year":"2004","unstructured":"McMillan, R., Wang, L., Tomer, A., Nichol, J., & Pistillo, J. (2004). Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 103, 1364\u20131369.","journal-title":"Blood"},{"key":"9100_CR3","first-page":"356","volume":"64","author":"W Stevens","year":"2006","unstructured":"Stevens, W., Koene, H., Zwaginga, J. J., & Vreugdenhil, G. (2006). Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Netherlands Journal of Medicine, 64, 356\u2013363.","journal-title":"Netherlands Journal of Medicine"},{"key":"9100_CR4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.hoc.2009.09.004","volume":"23","author":"JB Bussel","year":"2009","unstructured":"Bussel, J. B. (2009). Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematology\/Oncology Clinics of North America, 23, 1329\u20131341.","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"9100_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0609.2007.01000.x","volume":"69","author":"F Rodeghiero","year":"2008","unstructured":"Rodeghiero, F. (2008). First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. European Journal of Haematology. Supplementum, 69, 19\u201326.","journal-title":"European Journal of Haematology. Supplementum"},{"key":"9100_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00003495-200161050-00012","volume":"61","author":"CR Culy","year":"2001","unstructured":"Culy, C. R., & Spencer, C. M. (2001). Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs, 61, 641\u2013684.","journal-title":"Drugs"},{"key":"9100_CR7","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V95.5.1580.005k45_1580_1587","volume":"95","author":"A Raza","year":"2000","unstructured":"Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., et al. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood, 95, 1580\u20131587.","journal-title":"Blood"},{"key":"9100_CR8","first-page":"86","volume":"15","author":"SX Li","year":"2007","unstructured":"Li, S. X., Zhu, H. L., Lu, X. C., Fan, H., Yao, S. Q., et al. (2007). Amifostine used in the treatment of patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 86\u201390.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"9100_CR9","first-page":"440","volume":"13","author":"XC Lu","year":"2005","unstructured":"Lu, X. C., Zhu, H. L., Yao, S. Q., Fan, H., Zhuang, X. M., et al. (2005). Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, 440\u2013442.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"9100_CR10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995\u20131008.","journal-title":"New England Journal of Medicine"},{"key":"9100_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2007.01001.x","volume":"69","author":"A Newland","year":"2008","unstructured":"Newland, A. (2008). Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology. Supplementum, 69, 27\u201333.","journal-title":"European Journal of Haematology. Supplementum"},{"key":"9100_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000204251","volume":"91","author":"D Ben-Yehuda","year":"1994","unstructured":"Ben-Yehuda, D., Gillis, S., & Eldor, A. (1994). Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematologica, 91, 1\u20136.","journal-title":"Acta Haematologica"},{"key":"9100_CR13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2003-03-0900","volume":"103","author":"M Michel","year":"2004","unstructured":"Michel, M., Cooper, N., Jean, C., Frissora, C., & Bussel, J. B. (2004). Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 103, 890\u2013896.","journal-title":"Blood"},{"key":"9100_CR14","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","volume":"355","author":"JB Bussel","year":"2006","unstructured":"Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., et al. (2006). AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672\u20131681.","journal-title":"New England Journal of Medicine"},{"key":"9100_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1705775","volume":"40","author":"MN Dimopoulou","year":"2007","unstructured":"Dimopoulou, M. N., Gandhi, S., Ghevaert, C., Chakraverty, R., Fielding, A., et al. (2007). Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplantation, 40, 605\u2013606.","journal-title":"Bone Marrow Transplantation"},{"key":"9100_CR16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2354.2008.01032.x","volume":"18","author":"LG Marcu","year":"2009","unstructured":"Marcu, L. G. (2009). The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. European Journal of Cancer Care (England), 18, 116\u2013123.","journal-title":"European Journal of Cancer Care (England)"},{"key":"9100_CR17","doi-asserted-by":"crossref","unstructured":"Winczura P, Jassem J (2009) Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev.","DOI":"10.1016\/j.ctrv.2009.12.001"},{"key":"9100_CR18","first-page":"1035","volume":"84","author":"V Santini","year":"1999","unstructured":"Santini, V., & Giles, F. J. (1999). The potential of amifostine: From cytoprotectant to therapeutic agent. Haematologica, 84, 1035\u20131042.","journal-title":"Haematologica"},{"key":"9100_CR19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00277-002-0442-y","volume":"81","author":"N Viniou","year":"2002","unstructured":"Viniou, N., Terpos, E., Galanopoulos, A., Kritikou-Griva, E., Akel, S., et al. (2002). Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Annals of Hematology, 81, 182\u2013186.","journal-title":"Annals of Hematology"},{"key":"9100_CR20","first-page":"301","volume":"14","author":"H Fan","year":"2006","unstructured":"Fan, H., Zhu, H. L., Yao, S. Q., Lu, X. C., Zhuang, X. M., et al. (2006). Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 14, 301\u2013303.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-010-9100-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12013-010-9100-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-010-9100-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:40:27Z","timestamp":1592091627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12013-010-9100-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["9100"],"URL":"https:\/\/doi.org\/10.1007\/s12013-010-9100-5","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,21]]}}}